5 Healthcare Stocks Insiders Are Buying

Page 5 of 5

1. MapLight Therapeutics, Inc. (NASDAQ:MPLT)

On April 8, 2026, Needham initiated coverage of MapLight Therapeutics, Inc. (NASDAQ:MPLT) with a Buy rating and a $37 price target. Needham said the muscarinic class could be “disruptive” across multiple indications, including schizophrenia and Alzheimer’s disease psychosis, and noted ML-007C-MA may be “differentiated” from Cobenfy on tolerability and convenience, with potential to reach $1.5B in sales by 2035.

On April 7, 2026, TD Cowen initiated coverage of MapLight Therapeutics with a Buy rating, highlighting its pipeline targeting central nervous system and neuropsychiatric conditions. TD Cowen said the lead asset ML-007C-MA is positioned to improve on Cobenfy’s profile in schizophrenia, with a Phase II readout expected in Q3, and views the shares as undervalued based on this opportunity.

Last month, Canaccord initiated coverage of MapLight Therapeutics with a Buy rating and a $35 price target. Canaccord said the company’s focus on novel CNS therapeutics supports its schizophrenia opportunity and recommends buying the stock ahead of Phase 2 data for ML-007C-MA expected in Q3.

MapLight Therapeutics, Inc. (NASDAQ:MPLT) develops therapies for central nervous system disorders.

While we acknowledge the potential of MPLT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MPLT and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best Stocks That Beat Earnings Estimates and  10 Best 52-Week Low NASDAQ Stocks to Buy Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 5 of 5